Why Is Ustekinumab (IBD) So Expensive?(And How to Pay $5304 Instead)
Ustekinumab (IBD) averages $6800/month at US retail. Through Script Unlock pharmacy bidding, the same prescription typically costs $5304/month. Here's exactly why retail is so high — and how to stop paying it.
5 Real Reasons Ustekinumab (IBD) Costs So Much
Patent Protection
Ustekinumab (IBD) has active patent protection, giving the manufacturer a legal monopoly. With no generic competitor, they set any price they want. Patent lifecycles run 20 years from filing, often extended through minor reformulations or pediatric exclusivity.
PBM Spread Pricing
Pharmacy benefit managers (PBMs) sit between insurance plans and pharmacies. PBMs charge plans a higher price and pay pharmacies less — pocketing the spread. For high-volume drugs like Ustekinumab (IBD), this spread can be substantial. You see it as your copay; the PBM books it as profit.
Manufacturer Pricing Power
Ustekinumab (IBD)'s manufacturer sets the wholesale acquisition cost (WAC) — the "list price" — independent of production costs. US drug prices are not regulated at the federal level. WAC for Ustekinumab (IBD) has risen above the general inflation rate for the past decade, driving up both copays and uninsured cash prices.
Insurance Tier System
Insurance formularies place Ustekinumab (IBD) on a tier. Higher tiers mean higher copays — and tier placement depends partly on rebate deals between PBMs and the manufacturer, not on clinical evidence. If your plan assigns Ustekinumab (IBD) to tier 3 or higher, you absorb the cost of that negotiation.
Pharmacy Margin Variance
Pharmacies set their own cash prices for Ustekinumab (IBD). National chains target 30–40% margins using insurance reimbursement formulas even for cash patients. Independents often accept lower margins to win volume. Same Ustekinumab (IBD) script — $5304 at one pharmacy, $6800 at another, two miles apart.
The Middlemen Taking a Cut of Ustekinumab (IBD)
Between the factory and your medicine cabinet, 5 parties each take a margin on every $6800 you pay.
Script Unlock removes the PBM from the chain and lets pharmacies compete directly — collapsing the markup stack.
Ustekinumab (IBD) Price Has Risen ~186% Since 2016
Estimated average US retail price trend for Ustekinumab (IBD) over the past decade.
Historical estimates based on CMS NADAC data and PBM rate trends. Actual price growth varies by Ustekinumab (IBD) dose and formulation.
What You Can Do Right Now
5 actions that take under 10 minutes — most patients achieve the full 22% saving off Ustekinumab (IBD) retail.
- 1Compare cash prices via Script Unlock pharmacy bidding — Ustekinumab (IBD) bids average $5304/month (22% below the $6800 retail).
- 2Ask your prescriber about generic Ustekinumab. Same FDA-approved molecule, typically 70–90% cheaper than brand-name Ustekinumab (IBD).
- 3Request a 90-day supply of Ustekinumab (IBD) instead of monthly. Typical saving: 10–15% per fill.
- 4Check Ustekinumab (IBD) manufacturer patient assistance. If your income qualifies, the medication may be free or deeply discounted.
- 5Compare your insurance copay to the cash price every refill. For Ustekinumab (IBD), many patients pay less cash than their copay — especially before hitting the deductible.
“I was paying $6800/month until I found pharmacy bidding”
“I’d been filling Ustekinumab (IBD) at the same chain for two years — $6800 every month without question. I assumed that was just what it cost. My insurance covered some of it, but not enough. Then I uploaded the prescription to Script Unlock. Within five minutes I had four bids: $5304, $$5308, $$5313, and $$4760. The cheapest was an independent pharmacy I’d driven past a hundred times. I switched. I’m saving $1496/month — $17952/year. Same medication. Same dose. Same generic. The only thing different is someone competing for my prescription instead of assuming I’d just keep paying.”
— Representative patient experience based on Script Unlock Ustekinumab (IBD) bid data. Individual savings vary by zip code, dose, and quantity.
Pharmacies bid to win your Ustekinumab (IBD) prescription. Prices go lower than any pre-set coupon or discount card — because they’re competing against the pharmacy down the street.
Frequently Asked Questions — Why Ustekinumab (IBD) Costs So Much
Why is Ustekinumab (IBD) so expensive in the US?
Ustekinumab (IBD) is expensive primarily due to patent protection, PBM rebate inflation of list prices, and the absence of federal price negotiation. The US is the only high-income country without regulated or nationally negotiated drug pricing. The same Ustekinumab (IBD) costs 60–80% less in Canada, the UK, or Australia.
How much should Ustekinumab (IBD) actually cost?
Script Unlock pharmacy bidding regularly produces Ustekinumab (IBD) fills at $5304/month — close to the floor price most pharmacies can sustainably offer. That's 22% below the standard retail of $6800. The manufacturing cost of most small-molecule drugs is a tiny fraction of even this discounted price.
Why has the price of Ustekinumab (IBD) gone up?
Ustekinumab (IBD) retail prices have increased approximately 186% over the past decade — from around $2380 to $6800/month. Drivers include manufacturer list-price hikes, PBM rebate inflation, pharmacy chain consolidation, and the absence of a US price ceiling.
What is the cheapest way to get Ustekinumab (IBD)?
Cheapest path today: (1) Script Unlock pharmacy bids — avg $5304/month. (2) Generic Ustekinumab — typically 70–90% cheaper. (3) 90-day supply — saves ~15% per fill. (4) Manufacturer patient assistance if you qualify. (5) Compare cash to insurance copay — cash is often lower.
Is Ustekinumab (IBD) cheaper without insurance?
For many patients, yes. Ustekinumab (IBD) cash via Script Unlock ($5304/month) often costs less than the insurance copay — especially on tier 2/3 formulary plans. Compare every fill before paying via insurance.
Does Medicare cover Ustekinumab (IBD)?
Coverage depends on your specific Part D plan. Ustekinumab (IBD) is usually covered but tier placement and prior auth vary. In the donut hole (coverage gap), paying cash via Script Unlock ($5304/month) is often cheaper than the gap-phase copay. This is legal and allowed — no need to use insurance if the cash price is lower.
Compare Ustekinumab (IBD) prices now — pharmacies compete
Stop overpaying. Free. 60 seconds. No insurance card. Pharmacies bid on your Ustekinumab (IBD) prescription.
Stop Overpaying for Ustekinumab (IBD)Average saving: $1496/month · $17952/year